FDA panel votes unanimously for Eli Lilly's Alzheimer's treatment

The monoclonal antibody drug, delivered through an IV monthly for up to 18 months, would be the second Alzheimer's drug on the market if the FDA moves ahead to approve. The FDA's decision does not have to align with the panel's vote.

Leqembi has struggled to take off due to burdensome Medicare rules for use — including expensive brain scans — as well asEisai and Biogen have also asked the FDA to approve an injectable version of the drug, which would make it easier for patients to access. Mamie Laverock's Family Shares Photo of Actress' Hand from Her Hospital Bed Following Five-Story Fall7 Democrats who could replace Biden if he drops his 2024 reelection bid

Health Health Latest News, Health Health Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

Lilly Alzheimer’s Drug Seen Effective by FDA Advisory PanelEli Lilly & Co.’s treatment for Alzheimer’s disease works in at least some patients, according to a US advisory panel.
Source: BNNBloomberg - 🏆 83. / 50 Read more »

FDA Staff Proposes Narrow Approval for Lilly’s Alzheimer’s DrugUS drug regulatory staffers are considering a more targeted approval for Eli Lilly & Co.’s experimental Alzheimer’s disease treatment than the company wants, potentially limiting the market for a would-be blockbuster.
Source: BNNBloomberg - 🏆 83. / 50 Read more »